NEUROSENSE THERAPEUTICS LTD's ticker is and the CUSIP is M74240116. A total of 6 filers reported holding NEUROSENSE THERAPEUTICS LTD in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9 | -35.7% | 59,272 | +1.0% | 0.00% | – |
| Q2 2023 | $14 | -36.4% | 58,672 | +3.5% | 0.00% | -100.0% |
| Q1 2023 | $22 | +144.4% | 56,671 | -0.2% | 0.00% | – |
| Q4 2022 | $9 | -99.9% | 56,796 | +0.5% | 0.00% | – |
| Q3 2022 | $11,000 | -59.3% | 56,503 | +7.7% | 0.00% | -100.0% |
| Q2 2022 | $27,000 | +12.5% | 52,458 | +30.7% | 0.00% | -66.7% |
| Q1 2022 | $24,000 | – | 40,138 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Empery Asset Management, LP | 160,000 | $15,000 | 0.03% |
| Warberg Asset Management LLC | 66,606 | $61,000 | 0.01% |
| ARMISTICE CAPITAL, LLC | 425,000 | $388,000 | 0.01% |
| Hudson Bay Capital Management LP | 150,000 | $137,000 | 0.00% |
| UBS Group AG | 4,491 | $4,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |